Piramal Pharma's Altra Score Jumps to Bullish

Piramal Pharma Ltd. (PPLPHARMA) recently captured attention with a notable shift in its momentum profile. On 2026-07-16, the stock’s Altra Score – a proprietary 0-100 gauge of momentum derived from EMA alignment and RSI trend across daily, weekly, and monthly timeframes – jumped from a Neutral 58.6 to a Bullish 78.5. This nearly 20-point increase suggests a significant strengthening of its underlying price action, with higher scores indicating more bullish momentum.

Examining the technical details, PPLPHARMA is currently positioned above its key Exponential Moving Averages (EMAs), a classic sign of upward price pressure. This positive alignment was preceded by a bullish Weekly EMA Crossover on July 3, 2026, which often signals a potential shift in the intermediate-term trend. The Relative Strength Index (RSI) values are moderate across timeframes: 55.87 on the daily chart, 54.87 weekly, and 43.21 monthly. While the daily and weekly RSIs are comfortably above the 50-mark, indicating buying interest, the monthly RSI sits slightly lower, suggesting longer-term momentum is still building.

The context of the Nifty Pharma Sector further illuminates PPLPHARMA’s move. The sector itself demonstrates robust strength, reflected in an Altra Sector Score of 91.0, placing it as the #1 ranked sector with a Bullish classification. The Altra Sector Score is a similar momentum assessment applied at the sector level, also providing a relative-strength rank against other sectors in the same market. Nifty Pharma is identified as a “Confirmed leader, holding steady,” underpinned by a positive 4-week Relative Strength (RS) trend of +2.96, a healthy EMA spread of 5.63, and a strong RS RSI of 71.6. This strong sectorial backdrop provides a favorable environment for constituents like PPLPHARMA.

However, the broader market paints a more cautious picture. The Altra Market Score, which assesses overall market breadth by measuring the percentage of stocks above key EMAs, stands at a Mixed 48.2. Market analysis suggests “Mixed signals” and advises considering a reduction in position sizes. Breadth indicators reveal that only 52.0% of stocks are trading above their 20-day and 50-day EMAs, with an even lower 48.0% above the 200-day EMA. The market’s advances-to-declines ratio shows more stocks falling (29) than rising (21), and the 15-day Altra Score trend is negative at -1.0. This indicates that while specific pockets of the market, like the Pharma sector, are showing strength, the overall momentum of the market is not broadly supportive.

Despite the individual strength of Piramal Pharma and its sector, the fact that its “Top-Down Aligned” status is False, coupled with the tepid market breadth, suggests that traders and investors might approach this bullish shift with informed caution. While the stock’s internal momentum and strong sector leadership are compelling, the broader market’s mixed signals could introduce headwinds. This scenario underscores the importance of multi-timeframe analysis to understand both individual asset strength and the prevailing market texture.

What is the Altra Score? The Altra Score is AltraOne's proprietary momentum score for individual stocks, ranging from 0 to 100. It measures EMA structure and RSI momentum across multiple timeframes. A score above 60 is Bullish, below 40 is Bearish, and 40–60 is Neutral. The score is updated every trading day after market close based on end-of-day data.

Explore the full Signal History on AltraOne to see every EMA crossover signal across your watchlist — going back 52 weeks. The weekly EMA crossover is AltraOne's highest-conviction intermediate momentum signal; the Signal History page lets you track how these have played out over time.

Altra Score is a momentum indicator reflecting EMA alignment and RSI trend across daily, weekly, and monthly timeframes. It is not investment advice. Past momentum does not guarantee future performance. Please consult a SEBI-registered advisor before making investment decisions.